Replies to post #251461 on Biotech Values

[DewDiligence]

ONVO—Other FXR agonists for NASH (most notably ICPT’s Ocaliva) have failed due to pruritis and/or liver toxicity, so ONCO’s FXR314’s low rate of pruritis at the tested doses is what stands out. The question is whether the drug has enough efficacy at these doses to do more than merely reduce liver fat.